Key Points
- Chemed CEO Kevin McNamara sold 2,000 shares at an average price of $513.45, generating $1.03 million. He retains 66,418 shares valued at approximately $34.1 million.
- Chemed reported quarterly EPS of $6.06, exceeding estimates of $5.60, while revenue rose 8.8% year over year to $673.25 million. The company issued fiscal 2026 EPS guidance of $25.00–$25.75.
- The company increased its quarterly dividend to $0.70 from $0.60, equivalent to $2.80 annually and a 0.6% yield. Analysts maintain a consensus “Hold” rating with an average price target of $554.60.
Chemed Corporation (NYSE:CHE - Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of the business's stock in a transaction on Monday, September 28th. The stock was sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the completion of the sale, the chief executive officer directly owned 66,418 shares of the company's stock, valued at $34,102,322.10. This represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Chemed Stock Down 1.3%
Shares of NYSE:CHE opened at $505.60 on Thursday. The stock's 50-day moving average price is $523.48 and its 200-day moving average price is $461.28. Chemed Corporation has a 12-month low of $365.20 and a 12-month high of $557.00. The stock has a market capitalization of $6.61 billion, a P/E ratio of 25.39, a price-to-earnings-growth ratio of 2.06 and a beta of 0.51. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17.
Chemed (NYSE:CHE - Get Free Report) last released its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating analysts' consensus estimates of $5.60 by $0.46. The company had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. Chemed had a return on equity of 31.77% and a net margin of 10.60%.Chemed's revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, equities analysts anticipate that Chemed Corporation will post 23.55 earnings per share for the current year.
Chemed Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were given a $0.70 dividend. The ex-dividend date was Monday, August 17th. This is an increase from Chemed's previous quarterly dividend of $0.60. This represents a $2.80 annualized dividend and a yield of 0.6%. Chemed's dividend payout ratio is presently 14.06%.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in CHE. BlackRock Inc. purchased a new stake in shares of Chemed in the 2nd quarter worth about $691,290,000. TD Asset Management Inc increased its position in shares of Chemed by 7.5% during the fourth quarter. TD Asset Management Inc now owns 324,546 shares of the company's stock valued at $138,860,000 after buying an additional 22,715 shares during the period. Epoch Investment Partners Inc. raised its stake in Chemed by 4.9% in the fourth quarter. Epoch Investment Partners Inc. now owns 322,408 shares of the company's stock worth $137,945,000 after buying an additional 15,133 shares in the last quarter. First Trust Advisors LP raised its stake in Chemed by 24.7% in the first quarter. First Trust Advisors LP now owns 236,392 shares of the company's stock worth $89,295,000 after buying an additional 46,791 shares in the last quarter. Finally, Norges Bank purchased a new stake in Chemed in the fourth quarter worth about $76,067,000. 95.85% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on CHE. Oppenheimer lifted their target price on shares of Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Bank of America reissued a "neutral" rating on shares of Chemed in a report on Wednesday, July 29th. Weiss Ratings upgraded shares of Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Chemed from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 19th. Finally, Royal Bank Of Canada increased their target price on shares of Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Chemed presently has a consensus rating of "Hold" and an average price target of $554.60.
Get Our Latest Stock Report on Chemed
Chemed Company Profile
(
Get Free Report)
Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.
VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
